Roivant Sciences Ltd.
ROIV
$11.31
-$0.05-0.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.63% | -96.68% | -- | 132.66% | -- |
| Total Depreciation and Amortization | -40.81% | -22.87% | -- | -16.37% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -167.69% | 93.89% | -- | -362.67% | -- |
| Change in Net Operating Assets | 116.13% | -350.55% | -- | -81.34% | -- |
| Cash from Operations | -59.11% | 1.52% | -- | 22.85% | 39.44% |
| Capital Expenditure | -132.38% | -414.65% | -- | -139.45% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 9,419.15% | -97.05% | -- | -- | -- |
| Other Investing Activities | 12,275.68% | -- | -- | -- | -- |
| Cash from Investing | 15,405.11% | -91.32% | -- | -1,019.05% | -93.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -540.71% | -- | 76.58% | -- |
| Issuance of Common Stock | 254.88% | 216.57% | -- | -89.20% | -- |
| Repurchase of Common Stock | -958.59% | -7,505.64% | -- | -11,410.67% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -443.01% | -215.34% | -- | -8,935.31% | -115.51% |
| Foreign Exchange rate Adjustments | 42.81% | -135.08% | -- | -2,241.88% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 636.25% | -100.52% | -- | -253.51% | -189.36% |